|
|
||||||||
LETTERS TO THE EDITOR |





* Department of Biomedical Sciences, University of Catania, Catania, Italy
Experimental Oncology 1, and
Division of Pathology, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy
Department of Internal Medicine, University of Florence, Florence, Italy
In the September 1, 2004, issue of The Journal of Immunology, Sasso et al. (1) demonstrated an increased frequency of JH6 gene usage among t(14;18) translocations in B cells from hepatitis C virus (HCV)-infected individuals. We have recently detected bcl-2 rearrangement in lymphomas of MALT from HCV-infected patients (2). On the basis of the data reported by Sasso et al. (1), we sought to investigate which JH genes were preferentially used in our series. Nucleotide sequence analysis revealed that bcl-2 was joined to JH6 in all four HCV-associated MALT lymphomas with t(14;18) translocation (see Table I). Our data, supporting the findings by Sasso et al. (1), add that bcl-2 is frequently fused to JH6 in MALT lymphomas from HCV-infected patients. Additional studies are needed to better characterize the role of t(14;18) in lymphomagenesis among HCV-infected individuals.
|
References
Abbott Immunology, Abbott Park, IL 60064
The finding by Libra et al. (R1 ) that the t(14;18) in each of four HCV-associated MALT lymphomas used a JH6 gene is consistent with our finding that the t(14;18) found in PBMC of HCV+ subjects are strongly biased to use JH6 genes (R2 ). The authors have previously reported finding t(14;18) in HCV-associated MALT lymphomas (R3 ). An association has not been established, however, between MALT lymphomas and HCV infection or between MALT lymphomas and t(14;18). A better understanding of these areas will help place the present finding in proper context.
References
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |